Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06072430 · ClinicalTrials.gov registry record · Phase 3
A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)
A Phase 3 study of Sepsis and Septic Shock, sponsored by Vivacelle Bio.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 46
- Enrollment target
- 6
- Study locations
NCT06072430 is a Phase 3 study of Sepsis and Septic Shock that is actively recruiting participants, run by Vivacelle Bio. The registered enrollment target is 46 participants, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT06072430, a Phase 3 study of Sepsis and Septic Shock, is actively recruiting participants, sponsored by Vivacelle Bio.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 46 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.
Conditions Studied
Interventions
- DRUG VBI-S
Study Locations (6)
Arizona
- Dignity Health Chandler Regional Medical Center - Chandler
Georgia
- Memorial Health University Medical Center - Savannah
Missouri
- University Health - Kansas City
Nebraska
- Bryan Medical Center - Lincoln
North Carolina
- Novant Healthcare - Winston-Salem
Oregon
- Oregon Health & Science University (OHSU) - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2024-08-06 |
| Est. Completion | 2025-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06072430
The ClinicalTrials.gov registry entry for NCT06072430 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (99% lower). The listed sponsor is Vivacelle Bio, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which VBI-S is the first listed.
NCT06072430 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Arizona, Georgia, Missouri.
Frequently Asked Questions
What is clinical trial NCT06072430 about?
NCT06072430 is a clinical study titled "A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)". This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.
What is the current status of trial NCT06072430?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 46 participants. The study started on 2024-08-06. Estimated completion is 2025-12.
What conditions does trial NCT06072430 study?
This clinical trial studies the following conditions: Sepsis, Septic Shock, Hypovolemia.
What interventions are being tested in trial NCT06072430?
The interventions under investigation include: VBI-S (DRUG).
Who is sponsoring clinical trial NCT06072430?
This trial is sponsored by Vivacelle Bio, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06072430 being conducted?
This trial has 6 study locations across Arizona, Georgia, Missouri, Nebraska, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Limited Versus Extended Trophic Feeding (LET-FEED) Trial
RECRUITING · Phase 3
-
A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
COMPLETED · Phase 3
-
The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure
COMPLETED · Phase 3
-
Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants
COMPLETED · Phase 3
-
Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion
COMPLETED · Phase 3
-
The APS Phenotyping Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.